Financial Performance - The company achieved total operating revenue of 242 million yuan, an increase of 15.75% compared to the same period last year[23] - The net profit attributable to shareholders of the listed company was 13.0016 million yuan, representing a growth of 50.42% year-on-year[23] - The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 18.2514 million yuan, an increase of 107.88% compared to the previous year[23] - Total revenue for the quarter reached ¥242,063,684.65, an increase of approximately 15.7% compared to ¥209,134,132.83 in the previous period[27] - The company's operating revenue for the current period reached ¥242,063,684.65, representing a 15.75% increase compared to the same period last year[33] - Net profit attributable to shareholders was ¥13,001,623.68, marking a significant growth of 50.42% year-over-year[33] - The net profit after deducting non-recurring gains and losses increased by 107.88% to ¥18,251,415.69[33] - The net profit for the current period is CNY 36,074,251.24, compared to CNY 14,911,132.63 in the previous period, representing a growth of 141.5%[47] - The total comprehensive income for the current period is CNY 41,774,567.26, significantly higher than CNY 729,892.38 in the previous period[47] - The company reported a total profit of CNY 57,988,452.71, up from CNY 23,105,563.82, which is an increase of 150%[47] Cash Flow and Assets - The company received cash related to operating activities that increased by 1531%, mainly from external unit transactions[19] - The net cash flow from operating activities improved by 90.04%, totaling ¥70,573,746.91[33] - Cash flow from operating activities increased to CNY 70,573,746.91 from CNY 37,137,059.96, marking an increase of 90%[50] - Revenue from sales of goods and services received cash of CNY 294,299,249.39, up from CNY 231,787,697.08, indicating a growth of 27%[50] - Cash and cash equivalents increased to ¥535,049,843.40 from ¥479,210,709.13, reflecting a growth of approximately 11.7%[25] - The company's cash and cash equivalents increased by ¥55,839,134.27, with a closing balance of ¥535,049,843.40[32] - The cash inflow from investment activities totaled CNY 110,032,768.79, compared to CNY 329,896.60 in the previous period, showing a substantial increase[50] - The cash outflow from investment activities was CNY 121,835,582.49, resulting in a net cash flow from investment activities of CNY -11,802,813.70[50] Liabilities and Equity - The company's total liabilities increased to ¥734,350,448.95 from ¥696,935,426.18, representing a rise of approximately 5.4%[26] - The equity attributable to shareholders of the parent company reached ¥1,565,565,573.37, up from ¥1,545,394,966.62, indicating a growth of about 1.3%[27] Operational Metrics - Operating costs for the quarter were ¥185,573,350.49, slightly up from ¥185,038,994.01, indicating a marginal increase in operational expenses[27] - Research and development expenses amounted to ¥19,371,463.30, a decrease of about 6.9% from ¥20,806,658.60 in the previous period[27] - Inventory levels increased to ¥114,248,769.22 from ¥97,401,175.76, reflecting a rise of approximately 17.2%[25] - The total non-current assets increased to ¥1,318,821,743.47 from ¥1,292,300,817.82, showing a growth of about 2.1%[26] Other Financial Information - The company incurred share-based payment expenses of ¥4,064,000 due to the implementation of an employee stock ownership plan[42] - The weighted average return on net assets was 0.84%, an increase of 0.27% compared to the previous year[33] - The company reported a net cash outflow from financing activities of ¥2,714,178.14, an improvement from the previous year's outflow of ¥5,500,682.22[32] - The company has not disclosed any new product developments or market expansion strategies in the current report[23] - Other comprehensive income after tax for the current period is CNY 5,700,316.02, compared to a loss of CNY 14,181,240.25 in the previous period[47] - The company reported a net profit margin improvement, with net profit increasing to ¥55,733.16 from ¥415,610.41 in the previous period[27] - Non-operating income and expenses totaled -5,249,792.01 yuan, primarily due to public donations[5] - Contract liabilities increased by 121%, reflecting a rise in pre-received customer service orders[19] - Prepayments increased by 81%, driven by the procurement of Echosens equipment parts[19] - Other non-current assets rose by 137%, due to the new payment for land transfer fees[19] - The company reported a profit tax expense of CNY 21,914,201.47, compared to CNY 8,194,431.19 in the previous period, indicating an increase of 167%[47] - The company reported a net cash outflow from financing activities of ¥2,714,178.14, an improvement from the previous year's outflow of ¥5,500,682.22[32]

证券代码：300049 证券简称：福瑞股份 公告编号：2023-010 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）将于 2023 年 5 月 11 日(星期 四)15：00-17：00 在全景网举办 2022 年度业绩说明会。本次年度业绩说明会将采用网络 远程的方式举行，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本 次年度业绩说明会。 出席本次说明会的人员有：公司副董事长、总经理林欣先生（代行财务总监职责）， 董事会秘书孙秀珍女士，独立董事耿方圆先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投资 者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 10 日 15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公 ...

编号：2014-011 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------|------------------------|----------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称及人员姓 | | 湘财证券 魏巍 国信证券 李少思 益民基金管理有限公司 | | 名 | 蒋俊国 蔡立平 | | | 时间 | 2014 年 7 月 1 | 日 上午 9:30 | | 地点 | 福瑞股份 会议室 | | | 上市公司接待人员姓名 | 董事会秘书 林欣 | | | 投资者关系活动 | | 问：林总，我们是资本市场长期投资者，第一次来到公司，希望 | | 主要内容介绍 | | 对公司有个更深 ...

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2015- 012 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2015- 010 | --- | --- | --- | |----------------------------------|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2015- 007 | --- | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------- ...

Financial Performance - The company achieved a profit of over 45 million in the first three quarters, with a non-deductible profit of over 47 million [2] - The majority of domestic profits are contributed by pharmaceuticals, particularly from the "Love Liver" management center [2] International Sales - In 2014, approximately 100 units of Fibroscan were sold in the U.S., with around 90 units sold in 2015 so far, indicating significant growth [2] - The Fibroscan device is currently sold directly in Western Europe and China, with plans to start direct sales in the U.S. next year [3] Product Pricing and Competition - The cost for a single Fibroscan test ranges from 120 to 180 yuan [3] - There are currently no competitors for Fibroscan in the global market [3] Fibroscan Model and Production - The main model sold is Fibroscan 502, with the older model 402 being less common in the market [3] - Fibroscan's lifespan is rated at 8 years, and calibration is required after 6 months or 2000 tests, costing approximately 30,000 yuan in China [4] Love Liver Management Center - There are over 90 "Love Liver" management centers, which are in the process of expanding profitability [4] - The center has over 40,000 online members and approximately 100,000 offline members [4] Drug Portfolio - The company represents over 80 types of drugs, primarily antiviral and liver protection medications [4] Future Strategies - The company is preparing to establish a medical device company in Shenzhen for the production, research, and sales of Fibroscan in China [3] - Future acquisitions will focus on liver disease diagnostics and treatments, with both domestic and international options being considered [5]

编号：2015-017 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------|-----------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称及人员姓 | 国网英大集团 孙超 | | | 名 | | 深圳前海汇杰达理资本有限公司 解睿 | | 时间 | 2015 年 11 月 | 16 日 上午 10： 00 | | 地点 | 福瑞股份 会议室 | | | 上市公司接待人员姓名 | 董事会秘书 林欣 | | | 投资者关系活动 主要内容介绍 | 问：林总，今年完成 少 ...

Group 1: Strategic Partnerships and Investments - The company introduced three strategic shareholders, including KKR, Aobo, and Luxembourg, through capital increase and equity transfer, while maintaining control over Echosens [1] - The aim is to enhance technology and product offerings, focusing on becoming a leading company in liver assessment and diagnosis globally [2] Group 2: APP Development and User Engagement - The "Love Liver" health management APP is set to launch in May, with a target of developing 100,000 new members in the first phase and potentially activating an additional 400,000 users later [2] - The APP will facilitate communication between doctors and patients, allowing for direct interaction and feedback, enhancing patient experience and engagement [2] Group 3: Revenue and Financial Projections - Revenue from the "Love Liver" centers was approximately 15 million RMB last year, with projections of 80 million RMB for the current year [4] - The company aims to diversify its revenue streams into three areas: pharmaceutical sales, medical devices, and healthcare services, with a target of achieving a balanced revenue distribution over the next decade [4] Group 4: Market Potential and Competition - The liver disease market is significant, especially with the inclusion of fatty liver disease, which is reversible and has a large potential market [5] - The company acknowledges competition in the medical device sector but views it as a motivator for improving sales efforts and market focus [5]

Group 1: Company Transformation and Structure - In 2015, the company is undergoing a transformation towards medical services, focusing on several key areas including the establishment of 100 health management centers for liver disease [2][3]. - The company has restructured its operations, creating a pharmaceutical subsidiary in Jining, focusing on GMP and hospital formulations, while sales operations are centralized in Hohhot [2][3]. - The French subsidiary Echosens is responsible for medical diagnostic technology research and sales of medical devices [2][3]. Group 2: Financial Insights and Revenue Streams - A liver disease patient typically spends over 10,000 yuan annually on medication [3]. - The company aims to gradually increase the proportion of service revenue to a reasonable level, while maintaining stable growth in traditional pharmaceutical and instrument sales [4]. - The company has over 40 types of liver disease medications available for the health management centers [4]. Group 3: Development Plans and Collaborations - The company plans to enhance its online chronic liver management services and expand its range of liver disease medications [3]. - Collaboration with hospitals to establish health management centers is a priority, with each prefecture-level city targeted to have one center [4]. - The company provides advanced diagnostic tools like Fibroscan to partner hospitals, enhancing their academic image and reducing equipment investment [4]. Group 4: Management and Governance - The governance structure of Echosens will be improved to align with the company's strategic goals of becoming a leader in the global liver disease diagnostics industry [3]. - The management team regularly reports significant matters to ensure alignment with the company's objectives [3].